| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/19/2002 | WO2002072572A1 Quinolyl propyl piperidine derivatives, the preparation thereof and compositions containing same |
| 09/19/2002 | WO2002072559A1 Process to intermediates for biologically active compounds |
| 09/19/2002 | WO2002072553A1 Antiproliferative agents |
| 09/19/2002 | WO2002072549A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor |
| 09/19/2002 | WO2002072544A2 Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 09/19/2002 | WO2002072532A1 7, 9-substituted tetracycline compounds |
| 09/19/2002 | WO2002072527A2 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 09/19/2002 | WO2002072202A1 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| 09/19/2002 | WO2002072126A2 Invention relating to hcv diseases |
| 09/19/2002 | WO2002072123A1 Preventives or remedies for tumor or papillomaviral diseases |
| 09/19/2002 | WO2002072121A1 Composition for treating wssv infected tiger shrimp |
| 09/19/2002 | WO2002072120A1 Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases |
| 09/19/2002 | WO2002072112A1 Use of selenite or preparations containing selenite for treating wounds |
| 09/19/2002 | WO2002072111A1 Telithromycin suspension with a masked taste |
| 09/19/2002 | WO2002072108A1 Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial/matrix adhesion such as asthma, cystic fibrosis and influenza |
| 09/19/2002 | WO2002072102A1 Taste masked liquid pharmaceutical compositions |
| 09/19/2002 | WO2002072083A1 Novel inhibitors of formation of advanced glycation endproducts (ages) |
| 09/19/2002 | WO2002072081A1 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same |
| 09/19/2002 | WO2002072072A2 Granules and granules coated with a masked taste |
| 09/19/2002 | WO2002072066A1 Composition for rectal delivery of an oxazolidinone antibacterial drug |
| 09/19/2002 | WO2002072031A2 Substituted tetracycline compounds as synergistic antifungal agents |
| 09/19/2002 | WO2002072022A2 Substituted tetracycline compounds as antifungal agents |
| 09/19/2002 | WO2002072020A2 Novel anti-adhesive compounds and uses thereof |
| 09/19/2002 | WO2002072015A2 M cell directed vaccines |
| 09/19/2002 | WO2002071827A2 Retinoid x receptor modulators |
| 09/19/2002 | WO2002062361A9 Antiviral composition containing propolis and essential oils |
| 09/19/2002 | WO2002055532A3 Variant growth hormone molecules conjugated with macromolecular compounds |
| 09/19/2002 | WO2002053181A8 Enterohemorragic escherichia coli vaccine |
| 09/19/2002 | WO2002053138A3 Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens |
| 09/19/2002 | WO2002052934A3 Pesticidal and antiparasitic compositions |
| 09/19/2002 | WO2002050119A3 Method for modulating the binding activity of a novel icam-3 binding receptor on sinusoidal endothelial cells in liver and lymph nodes |
| 09/19/2002 | WO2002050028A3 Substituted benzoindoles as spla2 inhibitors |
| 09/19/2002 | WO2002038577A3 Extended release erythromycin derivatives |
| 09/19/2002 | WO2002033079A3 Human g-protein coupled receptor and uses thereof |
| 09/19/2002 | WO2002032919A3 6-o-substituted erythromycin derivatives having improved gastrointestinal tolerance |
| 09/19/2002 | WO2002030876A3 Cyclic carboxylic acids as integrin antagonists |
| 09/19/2002 | WO2002018341A3 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors |
| 09/19/2002 | WO2002014355A3 Novel mitogen activated kinase |
| 09/19/2002 | WO2002010192A3 Somatostatin analogues |
| 09/19/2002 | WO2002004487A3 Method for producing and using novel human defensins as biologically active proteins for treating infections and other illnesses |
| 09/19/2002 | WO2001097779A3 Improved injectable dispersions of propofol |
| 09/19/2002 | WO2001085208A8 Molecular antigen arrays and vaccines |
| 09/19/2002 | WO2001072702A3 Amidino compounds useful as nitric oxide synthase inhibitors |
| 09/19/2002 | WO2001063539A8 Anti-infective agents useful against multidrug-resistant strains of bacteria |
| 09/19/2002 | WO2001048248A3 High throughput screen for inhibitors of fatty acid biosynthesis in bacteria |
| 09/19/2002 | WO2001036630A9 Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same |
| 09/19/2002 | WO2001035899A9 Inhibitors of helicobacter pylori induced gastrointestinal diseases |
| 09/19/2002 | US20020133836 Methods to identify swine genetically resistant to F18 E. coli associated diseases |
| 09/19/2002 | US20020133022 Bactericides; grampositive bacteria |
| 09/19/2002 | US20020133021 Bactericides |
| 09/19/2002 | US20020132852 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use |
| 09/19/2002 | US20020132833 Caspase inhibitors and uses thereof |
| 09/19/2002 | US20020132822 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 09/19/2002 | US20020132814 AcrAB-like efflux pumps control resistance to drugs, even in highly resistant microbes; combination of an inhibitor of an AcrAB-like efflux pump and an antibiotic |
| 09/19/2002 | US20020132810 Novel heterocyclic amide derivatives |
| 09/19/2002 | US20020132796 Treatment or prevention of the diseases and conditions which respond to treatment by retinoids and or which in healthy mammals, including humans, are controlled by natural retinoic acid. |
| 09/19/2002 | US20020132795 Methods for treatment of neuro- and nephro- disorders and therapeutic toxicities using aminothiol compounds |
| 09/19/2002 | US20020132777 Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients |
| 09/19/2002 | US20020132775 Human potassium channel 1 and 2 proteins |
| 09/19/2002 | US20020132765 Powerful activity when administered orally and by injection so that they can be used in a hospital environment via injection, followed by an oral ambulatory treatment |
| 09/19/2002 | US20020132337 Processes for preparation of marek's disease virus using continuous avian cell lines |
| 09/19/2002 | US20020132297 Nucleotide sequences coding protein for use in the treatment nflammatory bowel disease, sepsis, viral diseases and rheumatoid arthritis |
| 09/19/2002 | US20020132236 Specific inhibitors of ribosome recycling factors (RRF) |
| 09/19/2002 | US20020132018 Use of non-alkalized cocoa solids in a drink |
| 09/19/2002 | US20020131983 Method for inducing an immunological response in a host by administering to the host at least one antigen and a lipoprotein |
| 09/19/2002 | US20020131980 Comprises an immunizing amount of Mycoplasma hyopneumoniae bacterin, an adjuvant mixture comprising an acrylic acid polymer, a metabolizable oil, a polyoxyethylene polypropylene block copolymer, and an pharmaceutically acceptable carrier |
| 09/19/2002 | US20020131951 Biodegradable poly(beta-amino esters) and uses thereof |
| 09/19/2002 | DE10112748A1 Erfindung betreffend HCV-Erkrankungen Invention concerning HCV disease |
| 09/19/2002 | DE10112215A1 Pharmazeutisches Kombinationspräparat The pharmaceutical combination product |
| 09/19/2002 | CA2473979A1 Method for identifying inhibitors of g protein coupled receptor signaling |
| 09/19/2002 | CA2457234A1 Substituted tetracycline compounds as antifungal agents |
| 09/19/2002 | CA2454959A1 Mva expressing modified hiv envelope, gag, and pol genes |
| 09/19/2002 | CA2441854A1 Composition for rectal delivery of an oxazolidinone antibacterial drug |
| 09/19/2002 | CA2441174A1 Novel anti-adhesive compounds and uses thereof |
| 09/19/2002 | CA2441088A1 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 09/19/2002 | CA2440834A1 Anti-epileptogenic agents |
| 09/19/2002 | CA2440773A1 Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules |
| 09/19/2002 | CA2440757A1 Substituted tetracycline compounds as synergistic antifungal agents |
| 09/19/2002 | CA2440618A1 Immunoglobulin superfamily proteins |
| 09/19/2002 | CA2440433A1 Cell culture system for synthesis of infectious hepatitis c virus |
| 09/19/2002 | CA2440412A1 Taste masked liquid pharmaceutical compositions |
| 09/19/2002 | CA2440353A1 Thiopeptide compounds |
| 09/19/2002 | CA2440209A1 Topical patch preparation containing a delayed-type hypersensitivity inducer and methods for using the same |
| 09/19/2002 | CA2440208A1 Tumour targeting prodrugs activated by metallo matrixproteinases |
| 09/19/2002 | CA2440131A1 Antibodies against human igg total fraction, and uses thereof in neutralising and treating hiv-1 |
| 09/19/2002 | CA2439301A1 Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases |
| 09/19/2002 | CA2438586A1 Retinoid x receptor modulators |
| 09/19/2002 | CA2438164A1 Use of preparations containing selenite or selenate |
| 09/19/2002 | CA2437958A1 Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| 09/19/2002 | CA2437756A1 Nucleic acid-associated proteins |
| 09/19/2002 | CA2434762A1 Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| 09/18/2002 | WO2001070237A1 Use of organophosphorous compounds for producing a medicament for treating infections |
| 09/18/2002 | EP1240903A2 Combination of calcium (3S) tetrahydro-3-furanyl(1S,2R)-3- [[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy) propylcarbamate with ritonavir |
| 09/18/2002 | EP1240899A2 Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections |
| 09/18/2002 | EP1240343A2 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 09/18/2002 | EP1240335A2 Proteases |
| 09/18/2002 | EP1240332A2 Streptococcus pyogenes virulence genes and proteins and their use |
| 09/18/2002 | EP1240330A2 i PSEUDOMONAS AERUGINOSA /i ANTIGENS |
| 09/18/2002 | EP1240329A2 i STREPTOCOCCUS PNEUMONIAE /i ANTIGENS |
| 09/18/2002 | EP1240328A1 Antigenic protein lppq of mycoplasma mycoides subsp. mycoides sc., its preparation and use |